UK markets closed

Nektar Therapeutics (0UNL.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
1.6606-0.0094 (-0.56%)
At close: 05:23PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.71
52-week change 3-26.72%
S&P500 52-week change 325.59%
52-week high 31.6894
52-week low 30.4350
50-day moving average 30.6536
200-day moving average 30.5960

Share statistics

Avg vol (3-month) 310.35k
Avg vol (10-day) 324.72k
Shares outstanding 5173.08M
Implied shares outstanding 6N/A
Float 8163.11M
% held by insiders 11.10%
% held by institutions 164.69%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-128.37%

Management effectiveness

Return on assets (ttm)-15.25%
Return on equity (ttm)-110.95%

Income statement

Revenue (ttm)90.12M
Revenue per share (ttm)0.47
Quarterly revenue growth (yoy)8.50%
Gross profit (ttm)N/A
EBITDA -127.41M
Net income avi to common (ttm)-276.06M
Diluted EPS (ttm)-2.6640
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)303.62M
Total cash per share (mrq)1.65
Total debt (mrq)230.4M
Total debt/equity (mrq)175.90%
Current ratio (mrq)6.45
Book value per share (mrq)0.68

Cash flow statement

Operating cash flow (ttm)-192.61M
Levered free cash flow (ttm)-63.63M